Financial Data and Key Metrics Changes - In Q4 2024, Zimmer Biomet achieved nearly 5% constant currency revenue growth, marking the 12th consecutive quarter of mid-single digit or better growth [10][32] - Adjusted earnings per share (EPS) grew by 6% to $8, with free cash flow reaching over $1 billion [32][50] - The company provided full-year 2025 financial guidance of constant currency revenue growth of 3% to 5% and adjusted EPS of $8.15 to $8.35, excluding the impact of the Paragon 28 acquisition [13][44] Business Line Data and Key Metrics Changes - The S.E.T. segment grew by 8.4%, with notable growth in CMFT at 13% and Sports at 22% [38] - Global knees grew by 5.6%, with U.S. growth at 3.9% and international growth at 8% [35] - Global hips grew by 4%, with U.S. growth at 3.2% and international growth at 4.8% [36] Market Data and Key Metrics Changes - The U.S. business grew by 4.7%, driven by strong high single-digit growth in S.E.T., while international growth was 5.2% [34] - The ASC market is rapidly expanding, with the company seeing a significant increase in sales from this segment, which has grown from 2-3% in 2019 to nearly 20% today [120] Company Strategy and Development Direction - The company plans to focus on people and culture, operational excellence, and innovation and diversification as key priorities for 2025 [15][26] - A four-point plan has been established to enhance performance in these areas, including leadership changes and a commitment to operational excellence in the U.S. market [16][17] - The acquisition of Paragon 28 is expected to enhance Zimmer Biomet's offerings in the foot and ankle space, complementing existing portfolios and driving growth [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of end markets, driven by an aging population, technological advancements, and a shift to outpatient procedures [12] - The company anticipates continued growth in the S.E.T. segment and expects to maintain a strong balance sheet post-acquisition of Paragon 28 [49][50] - Management acknowledged challenges from foreign exchange impacts but remains optimistic about achieving financial goals in 2025 [46][130] Other Important Information - The company reported a decline in the Technology and Data segment by 4.3% due to tough comparisons from the prior year [39] - Adjusted gross margin was 71.3%, lower than the previous year, primarily due to capitalized cost increases [41] - The company ended 2024 with $526 million in cash and cash equivalents and plans to continue share repurchases opportunistically [42][50] Q&A Session Summary Question: Guidance Philosophy for 2025 - Management indicated a more appropriate guidance range for 2025, considering one less selling day and potential drivers for upper range performance [55][58] Question: Integration of Paragon 28 - Management expressed confidence in minimal disruption during the integration of Paragon 28, highlighting the strong culture and innovation within the company [63][66] Question: Sales Growth and Margin Progression - Management provided insights on expected revenue growth and margin progression, indicating a stronger second half of 2025 due to new product uptake and easier comparisons [80][81] Question: EPS Growth Guidance - Management attributed the EPS guidance to foreign exchange impacts and emphasized the importance of investments for long-term growth [130] Question: ASC Opportunity - Management highlighted the significant growth potential in the ASC market, with plans to leverage the Paragon acquisition to enhance offerings in this space [120][123]

Zimmer Biomet (ZBH) reported $2.02 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 4.3%. EPS of $2.31 for the same period compares to $2.20 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.01 billion, representing a surprise of +0.53%. The company delivered an EPS surprise of +0.43%, with the consensus EPS estimate being $2.30.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.43%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.75 per share when it actually produced earnings of $1.74, delivering a surprise of -0.57%.Over the last four quarters, ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Media Investors Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results (WARSAW, IN) February 6, 2025 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31 ...

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ( ...

The upcoming report from Zimmer Biomet (ZBH) is expected to reveal quarterly earnings of $2.30 per share, indicating an increase of 4.6% compared to the year-ago period. Analysts forecast revenues of $2.01 billion, representing an increase of 3.7% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this ti ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open.See the Zacks Earnings Calendar to stay ahead of market-making news.In the last reported quarter, the company’s earnings of $1.74 missed the Zacks Consensus Estimate by 0.57%. ZBH beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average earnings surprise being 1.76%.Q4 Estimates for ZBHThe Zacks Consensus Estimate for revenues is pegged at $2.01 bi ...

Zimmer Biomet’s (ZBH) strategic product launches amid stabilizing market trends bolster our confidence in this stock. Yet, factors like macroeconomic uncertainties put pressure on the bottom line. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving ZBH's Share PriceZimmer Biomet has been witnessing strong market share gains within reconstructive Knees and Hips in key geographies in recent times despite macroeconomic challenges. The third quarter of 2024 marked the 11th consecutive quarter in ...

WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals ...

Company Overview - Zimmer Biomet Holdings Inc (NYSE: ZBH) is a prominent player in the Health Care Equipment Industry [1] - The company is strategically expanding its product portfolio, which could potentially alter its revenue growth trajectory [1] - Zimmer Biomet remains liquid and is well-positioned to execute its strategic initiatives [1] Industry Context - The Health Care Equipment Industry is a dynamic sector with significant growth potential [1] - Companies in this industry are focusing on product portfolio expansion to drive revenue growth [1] Strategic Initiatives - Zimmer Biomet is actively working on expanding its product offerings, which is a key strategy to enhance its market position [1] - The company's liquidity position supports its ability to invest in strategic growth initiatives [1]